Venture capital firms investing in biotech
3,001 investors have made two or more investments in biotech companies: 2,689 funds and 312 angels. SOSV, OrbiMed and New Enterprise Associates lead by biotech deal count, and Series A is the most crowded stage.
The most active investors in biotech
What the numbers say about biotech
3,001 investors with two or more biotech deals. 2,689 funds and 312 angels
SOSV leads by biotech deal count. 698 investments in biotech
Series A and Seed are neck and neck. 2,823 and 2,684 active investors
Family offices are rare here. 45 against 567 private-equity firms
How a founder raised from investors like these
Frequently asked
Does a biotech startup need a biotech-focused investor?
No. Most of the 3,001 are generalist funds with a handful of biotech deals; a focused thesis matters mainly at pre-seed and in capital-intensive sub-sectors. Look for the partner who led the fund's last biotech deal, not for the word in the fund's name.
How many investors do founders contact to get meetings?
Founders in our Raise Benchmarks reached 45 to 900 investors per round. Callie Care closed $480K from 3 investors after 10 first meetings. Besample reached 900 investors for 55 first meetings. Biotech rounds are crowded on both sides, so targeting matters more than volume.
How do I get a warm intro to a biotech investor?
Fundraisly's Warm Intro maps your team's LinkedIn connections against every investor in this database and shows which of these funds and angels a colleague can introduce you to.
Ready to fill your calendar?
Join 200+ founders who raised $1.1B with Fundraisly.
Founders get 10–50 qualified investor meetings in 90 days.